...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: The crick didn’t rise, here’s the presentation, finally!

Given Cenora has been chatting with Zenith the past few months one should consider it's them doing their own due diligence on development , market etc - there not working with Zenith so Zenith can play ball with another Pharma, they are the Pharma IMO. 

This news may inspire other Big Pharmas to act but it's my belief Cenora is going to capture this one.

glta 

Share
New Message
Please login to post a reply